Conference
A meta-analysis of trials of etoposide plus platinum agent versus irinotecan/topotecan plus platinum agent in first-line therapy of extensive stage small cell lung cancer (ES SCLC).
Abstract
e20019
Background: Etoposide plus a platinum agent (EP) represents the standard treatment of ES SCLC. A trial conducted in Japan demonstrated improved overall survival (OS) for irinotecan and cisplatin (IP), but subsequent trials could not consistently replicate these findings. Genotypic differences may explain these findings. These trials have not undergone systematic analysis. Methods: We conducted a systematic review and …
Authors
Ellis PM; Durocher-Allen L; Vella E; Sun A; Ung Y; Ramchandar K; Darling GE; Goffin JR
Volume
35
Pagination
pp. e20019-e20019
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2017
DOI
10.1200/jco.2017.35.15_suppl.e20019
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X